Skip to main content
. 2020 May 22;10:284. doi: 10.3389/fcimb.2020.00284

Table 4.

Treatment regimen and prognosis of patients with COVID-19.

Treatment n (percentage)
Antiviral 53 (100%)
Antibacterial 25 (47.2%)
Systemic corticosteroid 12 (22.6%)
Human γ-immunoglobulin 12 (22.6%)
Respiratory support 48 (90.5%)
Nasal cannula 12 (22.6%)
Non-invasive ventilation 32 (60.4%)
Improved and discharged 53 (100%)
Inpatient treatment 53 (100%)
Death 0 (0%)

Values are numbers (percentage).